The Nitric Oxide Prodrug JS-K Is Effective against Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species

Non–small-cell lung cancer is among the most common and deadly forms of human malignancies. Early detection is unusual, and there are no curative therapies in most cases. Diazeniumdiolate-based nitric oxide (NO)-releasing prodrugs are a growing class of promising NO-based therapeutics. Here, we show...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Maciag, Anna E., Chakrapani, Harinath, Saavedra, Joseph E., Morris, Nicole L., Holland, Ryan J., Kosak, Ken M., Shami, Paul J., Anderson, Lucy M., Keefer, Larry K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The American Society for Pharmacology and Experimental Therapeutics 2011
Aiheet:
Drug Discovery and Translational Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033717/
https://ncbi.nlm.nih.gov/pubmed/20962031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.110.174904
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia